Information Library

Results for: Faster product development - High-quality studies - Phase I/IIa - Phase II/III

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • A Focus on CNS

    Brochure — July 1, 2011
    Quintiles is your ally for broad and deep CNS expertise in every aspect of the drug development process.

  • The Molecular Biomarker Revolution in Non-Small Cell Lung Cancer

    White Paper — June 23, 2011
    In this new white paper Quintiles’ experts Christopher Ung, Jason Hill, Carrie Lee and Harish Dave review some of the most promising molecular pathways and targeted approaches for NSCLC, the critical role of diagnostics, and strategies to detect and address the emergence of resistance.

  • Outsourcing Oncology Molecular Biomarkers - Considerations for Emerging Countries

    Presentation — October 1, 2010
    Download Christopher Ung of Quintiles recent presentation, Outsourcing Oncology Molecular Biomarkers - Considerations for Emerging Countries from the Clinical Development of Cancer Drugs in China

  • Personalized Anti-Cancer Therapy Development in China

    Presentation — October 1, 2010
    Download the slides from Michael Shi, M.D. of Novartis recent presentation, Personalized Anti-Cancer Therapy Development in China from the Clinical Development of Cancer Drugs in China

  • Malaysia Prime Site

    Video — July 2, 2010
    Adam Chasse, Sr. Director, Access to Patients explains the importance of Prime Sites and the impact of our clinical research partnership with the University of Malaya Medical Centre in Malaysia.

  • Validated Biomarker Menu

    Brochure — July 14, 2009
    A comprehensive menu of validated cell, fluid and tissue based biomarker assays.

  • With so many CROs out there, which one is the best?

    Media Coverage — June 5, 2009
    PharmaceuticalJobSite.com decided "to try and determine which is the best CRO....we have decided on which CRO we feel has the best overall reputation."

  • Badania Kliniczne

    Brochure — April 10, 2009
    Quintiles Poland świadczy usługi związane z organizacją i monitorowaniem Badań Klinicznych faz I-IV. Każdy nowy lek - zanim będzie dostępny w sprzedaży- musi przejść fazę wszechstronnych, specjalistycznych testów i uzyskać aprobatę organów rejestracyjnych.

  • Monitoring for Quality

    White Paper — May 22, 2008
    Scott Cooley, Executive Director, Phase IIIb/IV Product Management, Quintiles, discusses innovative and traditional resources in a risk-based monitoring program.

Page 1 of 1 (9 results)

Subscribe to Email Based on Your Interests

Set preferences